SUMMARY A multicentred, randomised, blind study was started in 1978 to compare propranolol or hyaluronidase with placebo in patients with acute myocardial infarction admitted within 18 hours of onset of symptoms. Patients were randomised to group A and received hyaluronidase, propanolol, or placebo, or, if propranolol was contraindicated, to group B and received hyaluronidase or placebo. Hyaluronidase (500 U/kg given every six hours for 48 hours) had no effect on mortality or infarct size in the overall population. Because spontaneous reperfusion was more common in patients with early peaking of plasma creatine kinase MB or non-transmural electrocardiographic changes or both, the results were reanalysed for two subgroups: those in whom plasma creatine kinase peaked < 15 hours after the onset of symptoms (early peak, n = 184) and those with a peak > 15 h after the onset of symptoms (late peak, n = 546). The distribution of time to peak activity of creatine kinase MB was similar in the hyaluronidase and placebo groups. In the early peak patients who were given hyaluronidase (groups A and B) total mortality and cardiacspecific four year mortality were significantly lower. This was most pronounced in group B in which the total mortality was 45% and cardiovascular mortality was 47% less than in the placebo group. Similarly, mortality from cardiovascular disease in patients (groups A and B) with nontransmural ischaemia (ST-T changes) given hyaluronidase was significantly lower, with 
Effect of hyaluronidase on mortality and morbidity in patients with early peaking ofplasma creatine kinase 291 Left ventricular ejection fraction, a secondary end point in patients randomised to group B, increased more between entry (pretreatment) and 8-10 days later in patients treated with hyaluronidase than in the placebo group; this difference was only of borderline significance (p < 0-06).
To identify possible beneficial effects ofhyaluronidase in subgroups of patients, additional analyses were performed retrospectively and these analyses form the basis of the present report. Although we recognise that such retrospective subgroup analyses must be interpreted with caution and cannot provide definitive results, they can provide useful insights and-hypotheses for future testing.
Patients and methods
The overall design of the trial has been presented in detail"13; only aspects pertinent to the subgroup analyses are presented here.
PROSPECTIVE SUBGROUPS
The patients enrolled in MILIS were suspected of having acute myocardial infarction on the basis of chest pain and electrocardiographic changes. Analysis of the plasma activity of creatine kinase MB confirmed myocardial infarction in 87% of randomised patients.2 Patients were stratified prospectively into either group A (propranolol acceptable) or group B (propranolol contraindicated). The major reasons patients were entered into group B were moist rales involving a third or more ofthe lung fields (44%), ventricular rate of 55 beats/minute or less at randomisation or an episode of less than 40 beats/ minute before anticholinergic treatment (30%), systolic arterial pressure of less than 100 mm Hg, a decrease of 50 mm Hg (23%), pulmonary oedema (19%), and asthma (15%). Group A patients were randomised to placebo, propranolol, or hyaluronidase, and group B patients to either placebo or hyaluronidase. Patients were only admitted to the trial within 18 hours from the onset of symptoms.
RETROSPECTIVELY IDENTIFIED SUBGROUPS
Since the start ofthe trial in August 1978, substantial information has accrued which indicates that Q wave myocardial infarction is frequently caused by thrombotic coronary occlusion.4" There is also evidence to suggest that in some patients there is early spontaneous reperfusion67 which is more likely to be associated with early peaking of plasma creatine kinase MB and with only ST-T wave changes rather than Q waves.89 Presumably the early peaking reflects more rapid washout of the enzyme, which also occurs when pharmacological thrombolysis""l2 and mechanical intervention produce reperfusion."3 4 Non-Q-wave infarction is also associated with early peaking of plasma creatine kinase MB activity (a mean of 15 hours after onset of symptoms compared with patients with Q wave infarction in whom this peak occurs on average 17 hours after the onset of symptoms)."1 The results of early cardiac catheterisation show that Q wave infarction is associated with complete occlusion of the infarct related vessel. In contrast, non-Q-wave infarction is more likely to be caused by incomplete infarction, '6 suggesting that non-Q-wave infarction is associated with early reperfusion leaving extensive residual, viable but jeopardised myocardium.'7 The most recent implications for this hypothesis come from coronary angiography and thallium perfusion studies.'7 Extensive ischaemia (detected by thallium scintigraphy after exercise) and clinical events such as reinfarction and death were more common after non-Q-wave infarction than after Q wave infarction.
Retrospective analyses were performed to determine whether hyaluronidase had a different effect in patients suspected ofundergoing spontaneous reperfusion because they had early peaking of plasma creatine kinase MB activity or non-Q-wave changes on the pretreatment electrocardiogram. We compared the effects ofhyaluronidase and placebo on two end points: (a) mortality (both total and cardiovascular) and (b) the change in the left ventricular ejection fraction from the pretreatment value to that obtained 8-10 days after treatment. In the groups defined by the time to peak plasma creatine kinase MB we assessed only patients with confirmed myocardial infarction. In the group defined by the pretreatment electrocardiogram, patients were included if they satisfied the inclusion criteria, whether or not serial concentrations of plasma creatine kinase MB showed them to have sustained an acute myocardial infarction.
" toms." (c) Patients in whom spontaneous reperfusion 292 is suspected reach peak plasma creatine kinase MB activity from 12 to 26 hours after the onset of symptoms,'6 which is similar to the time at which creatine kinase MB peaks after pharmacologically induced reperfusion."' 12 Although there are limitations to the degree of correlation between the electrocardiogram and the anatomical extent of the infarct8'9 in this study, "non-transmural ischaemic changes" are taken to refer to ST segment depression without new Q waves. "Transmural ischaemic changes" refer to ST segment elevation or abnormal new Q waves or both. Sixty nine patients in whom electrocardiographic classification into non-trans. mural or transmural ischaemia was not possible were excluded from analysis (for example, patients with conduction defects on the pretreatment electrocardiogram).
Patients were followed up three and six months after discharge. Subsequently, semi-annual reports on the health of the patient were completed either by personal or telephone interview. Long-term follow up was obtained from all but two of the 851 patients. Follow up efforts were extended six months after recruitment ceased to attain a minimum of six months of follow up on all randomised patients. Survival curves and mortality rates are based on a cut off of four years of follow up experience. developed from baseline variables predictive of mortality in which there was some indication of imbalance between treatments. If the baseline ejection fraction used in the risk score was missing we used the mean ejection fraction among patients in whom the measurement was made. The covariance analysis of the change in the ejection fraction included the initial ejection fraction as an adjustment covariable.
Results

BASELINE CHARACTERISTICS
A total of 851 patients was analysed: 338 were in group A (172 randomised to placebo and 166 to hyaluronidase) and 513 were in group B (259 randomised to placebo and 254 to hyaluronidase). The Roberts, Braunwald, Muller, et al baseline characteristics (27 variables) were compared among patients who received either placebo or hyaluronidase in the entire patient group (n = 851), in those in group B (n = 513), in those with early peaking of creatine kinase MB curves (n = 184), and in patients showing non-transmural ischaemia (n = 146). There were few significant differences between patients treated with placebo and hyaluronidase in the entire patient group or in any of the subgroups, indicating good balance between the placebo treated and hyaluronidase treated groups.
INFARCT SIZE INDEX
Data for the calculation of the infarct size index were adequate in 133 patients treated with placebo or hyaluronidase with early peaking of plasma creatine kinase MB activity and 491 with late peaking. Mean (SD) infarct size index in the group with early peaking was 12 6 (1 2) creatine kinase g eq/m2, which was a mean of 67% of that in the late peaking group (18.9 (0 6), p < 0 0001). There was no significant difference in infarct size index assessed by plasma creatine kinase MB between the placebo treated and hyaluronidase treated groups for the total population or for prospectively identified subgroups.' In patients with "non-transmural" electrocardiographic changes in group B, the ejection fraction rose more (9-7 (2-7) units) on hyaluronidase than on placebo (1-9 (2-1) units) (p < 0-007) (table 4). Treatment with hyaluronidase in patients with "transmural" electrocardiographic changes did not improve ejection fraction either in groups A or B or in groups A and B together. Thus patients with a significant improvement in ejection fraction were found only in group B and were characterised by electrocardiographic findings of non-transmural ischaemia. In patients in group B who had early peaking of plasma creatine kinase MB activity there was also a tendency for hyaluronidase to improve ejection fraction.
Patients with "non-transmural" electrocardiographic changes were evenly distributed between Table 3 Comparison of the change in ejection fraction on different treatments by patientgroup and timefrom onset to peak creatine kinase MB plas concentration 296 kinase MB, hyaluronidase did not affect infarct size, and therefore the beneficial effect of hyaluronidase was not the result ofa reduction ofinfarct size. This is not unexpected, because treatment was started a mean of eight hours after the onset of symptoms. Instead, these findings suggest that the beneficial effect of hyaluronidase was mediated through some repair or healing process in the early recovery phase. The early peaking of plasma creatine kinase MB with more rapid washout of creatine kinase reflects better perfusion ofthe area ofinfarction. In addition, the infarct size index in patients with early peaking of creatine kinase MB was only about two thirds of that in patients with late peaking of creatine kinase MB. This could result from spontaneous reperfusion, better collateral flow to the ischaemic myocardium in the distribution ofthe occluded artery, or incomplete obstruction at the initiation of infarction. In any event, it is postulated that early peaking of plasma creatine kinase MB and electrocardiographic changes of non-transmural ischaemia reflect interruption of the evolution of infarction by reperfusion.'5 The following evidence supports this postulate. (a) Infarcts were smaller in patients with early peaking of plasma creatine kinase MB; values in this study were 12-6 for early peaking and 18-9 creatine kinase gram equivalents per square metre for late peaking, despite increased washout of creatine kinase that could lead to overestimation of infarct size. Similarly, infarct size in patients with transmural changes averaged 17-5 creatine kinase gram equivalents per square metre compared with only 6-1 in patients with nontransmural infarction. (b) There is a tendency for myocardial damage to be restricted to the subendocardium in such patients.' (c) The electrocardiogram of patients with early peaking of plasma creatine kinase MB is more likely to show non-Qwave infarction.2 ' (d) The changes.' 2 (g) Necropsy data show that contracture necrosis and haemorrhage are more common in non-Q-wave infarction than Q wave infarction," suggesting that reperfusion is more common in the former group.
It is possible that the beneficial effects ofhyaluronRoberts, Braunwald, Muller, et al idase in patients with early peaking ofcreatine kinase MB and non-transmural electrocardiographic changes are related to the concomitant improved perfusion of the ischaemic and necrotic myocardium, which would provide a greater access for hyaluronidase to the injured myocardium and permit it to exert its beneficial effect. One hypothesis is that hyaluronidase accelerates recovery of function in surviving but "stunned""30 myocardium, which would account for the improved ventricular function. Experimental studies have shown that hyaluronidase reduces swelling of ischaemic myocytes and increases peifusion of ischaemic myocardium,3" an effect that might attenuate the "no reflow" phenomenon.353' The hypothesis that the drug exerts its effect only with improved perfusion is consistent with the observation that we saw no beneficial effect in patients with late peaking of plasma activity of creatine kinase MB who presumably do not undergo spontaneous reperfusion.
Hyaluronidase has been shown to cause a short term increase in collateral blood flow3 and a degradation product of hyaluronidase has been shown to stimulate the growth of new blood vessels." '7 Effect of hyaluronidase on mortality and morbidity in patients with early peaking ofplasma creatine kinase 297 hospital mortality rate for placebo treated patients in group A was 4%, and the total one year and four year mortality rates were 12% and 15%, respectively.
Even if hyalurodinase had a moderately beneficial effect, it could be detected only with a much larger sample of such patients. On the other hand, in group B the left ventricular ejection fraction was significantly lower at entry (mean 44%). In the placebo treated patients in group B, the ejection fraction at hospital discharge was 46%, and the in-hospital, one year, and four year mortality rates (12%, 25%, and 37%, respectively) were significantly higher than in group A. Thus in group B the extent of depression of left ventricular function and the mortality rate in the placebo treated group were such that even if only moderate improvement was produced by the drug it would be detected.
In conclusion, these retrospective findings provide supportive evidence for the beneficial effect of hyaluronidase that was suspected from the analyses carried out on prospectively identified subgroups. The beneficial effect was manifest by both improved ventricular function and survival and occurred in patients in group B. The principal features of the patient population that benefited from hyaluronidase were early peaking ofplasma creatine kinase MB and non-transmural changes on the entry electrocardiogram. It may be that in the presence of acute infarction and reperfusion or residual blood flow, hyaluronidase exerts a beneficial effect, resulting in improved left ventricular function. In view of the widespread current use of thrombolytic treatment in patients with acute myocardial infarction, these findings may have important implications for the potential benefits when hyaluronidase is used in combination with reperfusion.
Because the data in this paper are derived from a retrospective subgroup analysis the strength of the conclusions is limited. Therefore, the hypothesis that hyaluronidase has a beneficial effect in these subgroups requires confirmation in prospective studies. In view of the internal consistency of the findings in this study, however, and the increasing importance of reperfusion treatment in acute myocardial infarction, which creates a patient group that is perhaps not unlike the retrospectively identified subgroup which benefited from hyaluronidase in MILIS, such studies deserve serious consideration. 
